Clover Biopharmaceutical IPO: Covid-19 Vaccine Candidate Shows Strong Potential

326 Views14 Oct 2021 22:29
Clover’s most advanced drug asset is a Covid-19 vaccine candidate, SCB-2019 and the company expects to receive conditional approval in the near future. Protein-based Covid vaccines have shown safety..
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
chart-bar
x